A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.

Inclusion Criteria: * LDL-C \> 70 mg/dL and TG \< 400 mg/dL, * Treated with a stable statin therapy; Atorvastatin 20/40 or Simvastatin 10/20 Exclusion Criteria: * BMI \> or =35 kg/m2 * Significant cardiovascular disease * HbA1c \> 10% * Uncontrolled hypertension * Active muscle disease * GFR \< 60 ml/min * Hepatic dysfunction * Anemia * Existing CETP deficiency * History of Homozygous Familial Hypercholerstrolemia * History of malignancy * Alcohol abuse * Treatment with investigational product * Treatment with PCSK9 * Clinically significant condition * Known CETP inhibitor allergy